Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a good long-term biotech to own in my opinion. That's because it has already been able to receive regulatory approvals for several of its drugs in its pipeline. Matter of fact, the drugs being sold by the company are Crysvita and Dojolvi. This isn't the only program to drive the stock price higher, either. Another promising program would be the advancement of setrusumab for the treatment of pediatric and young adults of osteogenesis imperfecta [OI] subtypes I, ...